More than 10 loss-making biotechnology companies have filed for Hong Kong stock exchange listings this year, bringing cutting-edge drugs and artificial intelligence-powered drug discovery platforms to market, as the city’s bourse presses ahead with reforms aimed at supporting the real economy. The latest applications came as healthcare and biotechnology equity capital market activity – stock sales by companies and their shareholders – in Hong Kong reached US$15.6 billion last year, the second...